

Richard M Goldberg

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7328363/richard-m-goldberg-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

121
papers

20,840
citations

43
h-index

137
g-index

137
ext. papers

25,132
ext. citations

8.4
avg, IF

5.89
L-index

#	Paper	IF	Citations
121	Impact of diabetes and metformin use on recurrence and outcome in stage II-III colon cancer patients-A pooled analysis of three adjuvant trials.. <i>European Journal of Cancer</i> , 2022 , 166, 100-111	7.5	1
120	Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. <i>Oncogene</i> , 2021 ,	9.2	2
119	Survival in Young-Onset Metastatic Colorectal Cancer: Findings from Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	4
118	Molecular differences between lymph nodes and distant metastases compared with primaries in colorectal cancer patients. <i>Npj Precision Oncology</i> , 2021 , 5, 95	9.8	1
117	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 3234-3242	12.9	5
116	Prospective Statewide Study of Universal Screening for Hereditary Colorectal Cancer: The Ohio Colorectal Cancer Prevention Initiative. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	6
115	Genetically Predicted Circulating C-Reactive Protein Concentration and Colorectal Cancer Survival: A Mendelian Randomization Consortium Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 1349-1358	4	1
114	Large-scale analysis of KMT2 mutations defines a distinctive molecular subset with treatment implication in gastric cancer. <i>Oncogene</i> , 2021 , 40, 4894-4905	9.2	2
113	Diagnosis of digestive system tumours. <i>International Journal of Cancer</i> , 2021 , 148, 1040-1050	7.5	10
112	IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkaa074	4.6	2
111	Genetic Predictors of Severe Skin Toxicity in Patients with Stage III Colon Cancer Treated with Cetuximab: NCCTG N0147 (Alliance). <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021 , 30, 404-411	4	0
110	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021 , 144, 101-112	7.5	4
109	Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021 , 13, 17588359211020547	5.4	2
108	Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials. <i>Journal of Clinical Oncology</i> , 2021 , 39, 642-651	2.2	27
107	Association of Adiponectin and Vitamin D With Tumor Infiltrating Lymphocytes and Survival in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2021 , 5, pkab070	4.6	
106	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	3
105	-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype. <i>Cancers</i> , 2020 , 12,	6.6	7

104	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa023	4.6	16
103	Molecular profile of BRCA-mutated biliary tract cancers. <i>ESMO Open</i> , 2020 , 5, e000682	6	34
102	Molecular Analyses of Left- and Right-Sided Tumors in Adolescents and Young Adults with Colorectal Cancer. <i>Oncologist</i> , 2020 , 25, 404-413	5.7	13
101	Genetic Variant Associated With Survival of Patients With Stage II-III Colon Cancer. <i>Clinical Gastroenterology and Hepatology</i> , 2020 , 18, 2717-2723.e3	6.9	3
100	Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405. <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkaa024	4.6	4
99	The impact of ARID1A mutation on molecular characteristics in colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 140, 119-129	7.5	13
98	Molecular Characterization of Appendiceal Goblet Cell Carcinoid. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2634-2640	6.1	4
97	Comprehensive Genomic Profiling of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs). <i>Clinical Cancer Research</i> , 2020 , 26, 5943-5951	12.9	17
96	Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 2146-2154	6.1	8
95	Diabetes and Clinical Outcome in Patients With Metastatic Colorectal Cancer: CALGB 80405 (Alliance). <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz078	4.6	12
94	Relationship between MLH1, PMS2, MSH2 and MSH6 gene-specific alterations and tumor mutational burden in 1057 microsatellite instability-high solid tumors. <i>International Journal of Cancer</i> , 2020 , 147, 2948-2956	7.5	32
93	Plasma 25-Hydroxyvitamin D Levels and Survival in Patients with Advanced or Metastatic Colorectal Cancer: Findings from CALGB/SWOG 80405 (Alliance). <i>Clinical Cancer Research</i> , 2019 , 25, 7497-7505	12.9	21
92	Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 3096-3103	12.9	30
91	The current state of molecular testing in the treatment of patients with solid tumors, 2019. <i>Ca-A Cancer Journal for Clinicians</i> , 2019 , 69, 305-343	220.7	86
90	Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1217-1227	2.2	140
89	Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors. <i>Oncologist</i> , 2019 , 24, 319-326	5.7	19
88	Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2620-2631	2.2	26
87	Relative contribution of clinical and molecular features to outcome within low and high risk T and N groups in stage III colon cancer (CC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3520-3520	2.2	4

86	Molecular landscape of colorectal cancers harboring R-spondin fusions.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3588-3588	2.2	3
85	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. <i>Molecular Cancer Research</i> , 2018 , 16, 805-812	6.6	114
84	Hypermutated Tumors and Immune Checkpoint Inhibition. <i>Drugs</i> , 2018 , 78, 155-162	12.1	16
83	Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer. <i>JAMA Oncology</i> , 2018 , 4, 806-813	13.4	85
82	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 379-383	13.4	64
81	Promising New Agents for Colorectal Cancer. <i>Current Treatment Options in Oncology</i> , 2018 , 19, 29	5.4	35
80	Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer. <i>Cancer</i> , 2018 , 124, 3118-3126	6.4	14
79	In Reply. <i>Oncologist</i> , 2018 , 23, 136	5.7	
78	Comprehensive population-wide analysis of Lynch syndrome in Iceland reveals founder mutations in MSH6 and PMS2. <i>Nature Communications</i> , 2017 , 8, 14755	17.4	56
77	Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2392-2401	27.4	434
76	Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. <i>Science</i> , 2017 , 357, 409-413	41.3	3274
75	Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. <i>JAMA Oncology</i> , 2017 , 3, 472-480	13.4	59
74	Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	138
73	Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer. <i>JAMA Oncology</i> , 2017 , 3, 464-471	13.4	335
72	Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1929-1937	2.2	28
71	Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3338-3346	2.2	45
70	Primary Tumor Sidedness as Prognostic and Predictive Biomarker in Metastatic Colorectal Cancer: Further Validation of a Potentially Practice-Changing Variable. <i>JAMA Oncology</i> , 2017 , 3, 165-166	13.4	10
69	Impact of overall severity of adverse events (AEs) on long-term outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line systemic chemotherapy: Findings from 3,971 pts in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3582-3582	2.2	0

68	Colorectal clinical trials: what is on the horizon?. <i>Future Oncology</i> , 2016 , 12, 525-31	3.6	1
67	Patients with colorectal cancer associated with Lynch syndrome and MLH1 promoter hypermethylation have similar prognoses. <i>Genetics in Medicine</i> , 2016 , 18, 863-8	8.1	24
66	Body Mass Index Is Prognostic in Metastatic Colorectal Cancer: Pooled Analysis of Patients From First-Line Clinical Trials in the ARCAD Database. <i>Journal of Clinical Oncology</i> , 2016 , 34, 144-50	2.2	76
65	Programmed death-1 blockade in mismatch repair deficient colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 103-103	2.2	41
64	Programmed death-1 blockade in mismatch repair deficient cancer independent of tumor histology.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3003-3003	2.2	21
63	Impact of primary (1 st) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of CALGB/SWOG 80405 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3504-3504	2.2	193
62	Association of tumor infiltrating lymphocytes (TILs) with molecular subtype and prognosis in stage III colon cancers (CC) from a FOLFOX-based adjuvant chemotherapy trial.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3518-3518	2.2	4
61	Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).. <i>Journal of Clinical Oncology</i> , 2016 , 34, 192-192	2.2	59
60	Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 584-584	2.2	
59	Therapeutic impact and timing of gastrointestinal malignancy genomic profiling: A single-institution experience.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 4100-4100	2.2	
58	Molecular markers and survival after recurrence in stage III colon cancers from NCCTG N0147 and NSABP C-08 adjuvant chemotherapy trials.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3600-3600	2.2	1
57	Alcohol consumption and colon cancer prognosis among participants in north central cancer treatment group phase III trial N0147. <i>International Journal of Cancer</i> , 2016 , 139, 986-95	7.5	11
56	Highlights in Gastrointestinal (Colorectal) Cancer Treatment: The Primary Tumor Sidedness Debate and Advances in Immunotherapy. <i>JAMA Oncology</i> , 2016 , 2, 1537-1538	13.4	5
55	Racial Differences in BRAF/KRAS Mutation Rates and Survival in Stage III Colon Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	67
54	Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. <i>Lancet Oncology</i> , 2015 , 16, 937-48	21.7	240
53	Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). <i>Clinical Cancer Research</i> , 2015 , 21, 5294-304	12.9	53
52	Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. <i>Gastroenterology</i> , 2015 , 148, 88-99	13.3	219
51	Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: findings from the analysis and research in cancers of the digestive system database. <i>Journal of Clinical Oncology</i> , 2015 , 33, 22-8	2.2	69

50	Reply to J.N. Primrose et al and C.-H. Kline. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2408-9	2.2	3
49	PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. <i>New England Journal of Medicine</i> , 2015 , 372, 2509-20	59.2	5560
48	Update on Anti-Angiogenesis Therapy in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 378-387	1	8
47	Alcohol consumption and prognosis in patients with stage III colon cancer: A correlative analysis of phase III trial NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1508-1508	2.2	1
46	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3507-3507	2.2	6
45	Subgroup analysis of patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG) in the CORRECT trial who had progression-free survival (PFS) longer than 4 months.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 710-710	2.2	2
44	Upfront molecular testing in patients with advanced gastro-esophageal cancer: Is it time yet?. <i>Oncotarget</i> , 2015 , 6, 22206-13	3.3	6
43	Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147).. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3590-3590	2.2	1
42	Outcomes for FOLFIRI plus bevacizumab (BEV) or cetuximab (CET) in patients previously treated with oxaliplatin-based adjuvant therapy: A combined analysis of data from FIRE-3 and CALGB 80405.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3585-3585	2.2	
41	KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). <i>Clinical Cancer Research</i> , 2014 , 20, 3033-43	12.9	105
40	How Can Next-Generation Sequencing (Genomics) Help Us in Treating Colorectal Cancer?. <i>Current Colorectal Cancer Reports</i> , 2014 , 10, 372-379	1	6
39	Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	109
38	Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. <i>Hepatic Oncology</i> , 2014 , 1, 331-345	4	
37	DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147). <i>Journal of the National Cancer Institute</i> , 2014 , 106,	9.7	101
36	Overall survival result and outcomes by KRAS, BRAF, and DNA mismatch repair in relation to primary tumor site in colon cancers from a randomized trial of adjuvant chemotherapy: NCCTG (Alliance) N0147.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3525-3525	2.2	7
35	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRCA).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1818-1818	2.2	60
34	CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRCA).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 1818-1818	2.2	131
33	Tolerability and efficacy of modified FOLFIRINOX (mFOLFIRINOX) in patients with borderline-resectable pancreatic cancer (BRPC) and locally advanced unresectable pancreatic cancer (LAURPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 275-275	2.2	2

32	Racial differences in KRAS/BRAF mutation rates and survival in colon cancer (NCCTG N0147 [Alliance]).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3536-3536	2.2	
31	Body mass index (BMI) as prognostic in metastatic colorectal cancer (mCRC): A pooled analysis of 21 first-line trials in the ARCAD database.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3537-3537	2.2	
30	Effect of genetic counseling on detection of Lynch syndrome (LS) in colorectal cancer (CRC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 419-419	2.2	
29	Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2013 , 381, 303-12	4.0	1783
28	Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3664-72	3.2	192
27	UGT1A1 genotype-guided phase I study of irinotecan, oxaliplatin, and capecitabine. <i>Investigational New Drugs</i> , 2013 , 31, 1559-67	4.3	14
26	How we treat metastatic colon cancer in older adults. <i>Journal of Geriatric Oncology</i> , 2013 , 4, 295-301	3.6	10
25	Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: findings from CALGB 89803 and CALGB 80405. <i>Clinical Colorectal Cancer</i> , 2013 , 12, 95-102	3.8	13
24	Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance). <i>Clinical Cancer Research</i> , 2013 , 19, 6957-66	12.9	79
23	Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1383-93	27.4	330
22	2010 Staging System for Colon and Rectal Carcinoma. <i>Annals of Surgical Oncology</i> , 2011 , 18, 1513-1517	3.1	11
21	Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. <i>Journal of Clinical Oncology</i> , 2011 , 29, 11-6	2.2	457
20	Vitamin D status in patients with stage IV colorectal cancer: findings from Intergroup trial N9741. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1599-606	2.2	71
19	Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3385-90	2.2	220
18	Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer. <i>Gastrointestinal Cancer Research: GCR</i> , 2009 , 3, S23-7		2
17	Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. <i>Clinical Cancer Research</i> , 2008 , 14, 8263-9	12.9	50
16	As Federal Funding for Cancer is Cut, Researchers Struggle. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 165		
15	The continuum of care: a paradigm for the management of metastatic colorectal cancer. <i>Oncologist</i> , 2007 , 12, 38-50	5.7	190

14	End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4569-74	2.2	183
13	Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. <i>Journal of Clinical Oncology</i> , 2007 , 25, 3456-61	2.2	351
12	Which strategies will lead to progress in the management of colorectal cancer?. <i>Gastrointestinal Cancer Research: GCR</i> , 2007 , 1, S33-6		
11	Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3347-53	2.2	179
10	Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8664-70	2.2	509
9	Optimizing adjuvant therapy for colon cancer: Ongoing investigations. <i>Current Colorectal Cancer Reports</i> , 2005 , 1, 27-33	1	
8	Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2004 , 54 Suppl 1, S57-64	3.5	14
7	A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2004 , 22, 23-30	2.2	1885
6	Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. <i>New England Journal of Medicine</i> , 2003 , 349, 247-57	59.2	1641
5	Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program. <i>Journal of Clinical Oncology</i> , 2002 , 20, 4591-6	2.2	31
4	Adjuvant chemotherapy for colon cancer. <i>Current Oncology Reports</i> , 2001 , 3, 94-101	6.3	9
3	A flexible design for multiple armed screening trials. <i>Statistics in Medicine</i> , 2001 , 20, 1051-60	2.3	61
2	Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. <i>Cancer</i> , 1996 , 77, 1284-91	6.4	87
1	Gastrointestinal Cancers81-104		